Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R).: Rationale for the study and protocol design

被引：38

作者：

Valgimigli, Marco ^{[1
,2
]}

Campo, Gianluca ^{[1
]}

de Cesare, Nicoletta ^{[3
]}

Vranckx, Pascal ^{[4
]}

Hamon, Martial ^{[5
]}

Angiolillo, Dominick J. ^{[6
]}

Sabate, Manel ^{[7
]}

Ferrari, Fabrizio ^{[1
]}

Furgieri, Alessandro ^{[8
]}

Tumscitz, Carlo ^{[9
]}

Repetto, Alessandra ^{[10
]}

Colangelo, Salvatore ^{[11
]}

Meliga, Emanuele ^{[12
]}

Kubbajeh, Moh'd ^{[13
]}

Parrinello, Giovanni ^{[14
]}

Percoco, Gianfranco ^{[13
]}

Ferrari, Roberto ^{[1
,2
]}

机构：

[1] Univ Ferrara, Arcispedale S Anna Hosp, Cardiovasc Inst, I-44100 Ferrara, Italy

[2] IRCCS, Salvatore Maugeri Fdn, Cardiovasc Res Ctr, Gussago, BS, Italy

[3] Policlin S Marco, Zingonia, BG, Italy

[4] Virga Jesseziekenhuis, Hasselt, Belgium

[5] Univ Hosp Caen, Normandy, France

[6] Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA

[7] St Paul Univ Hosp, Dept Cardiol, Intervent Cardiol Unit, Barcelona, Spain

[8] Villa Maria Cecilia Hosp, Dept Med & Surg Cardiol, Cotignola, RA, Italy

[9] Guglielmo da Saliceto Hosp, Dept Cardiol, Piacenza, Italy

[10] Policlin San Matteo, Ist Ricovero & Cura Carattere Sci, Pavia, Italy

[11] San Giovanni Bosco Hosp, Cardiovasc Intervent Lab, Turin, Italy

[12] Azienda Osped S Giovanni Battista, Unit Cardiol, Turin, Italy

[13] Lagosanto Hosp, Lagosanto, Italy

[14] Univ Brescia, Med Stat Unit, Brescia, Italy

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 2008年 / 22卷 / 04期

关键词：

aspirin resistance; clopidogrel resistance; tirofiban; platelet inhibition;

D O I：

10.1007/s10557-008-6121-z

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Purpose To assess whether glycoprotein IIb/IIIa inhibition using tirofiban in low risk patients undergoing percutaneous coronary intervention (PCI) may reduce the risk of periprocedural myocardial infarction compared to standard care in poor responders to aspirin and/or clopidogrel. Methods We will enroll patients at ten European sites or more to participate in the Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel (3T/2R) study with a pre-specified sample size of 240 patients out of 1,100 or more who will undergo screening. The primary outcome measure is troponin I or T elevation ratio at least three times the upper limit of normal within 48 h after completion of the PCI. Conclusion The results of 3T/2R study will evaluate whether tailored intensification of anti-platelet treatment based on poor individual response to oral anti-platelet agents may modulate the risk of periprocedural myocardial infarction during PCI. Our findings attempt at unraveling a new era of individualized anti-platelet treatment through the use of point-of-care assessment.

引用

页码：313 / 320

页数：8

共 51 条

[1]

Influence of Aspirin resistance on platelet function profiles in patients on long-term Aspirin and Clopidogrel after percutaneous coronary intervention [J].